Aortic stenosis resident survival guide
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Synonyms and keywords: AS; critical AS; tight AS; aortic valve stenosis; calcific aortic stenosis; senile calcific aortic stenosis; degenerative calcific aortic stenosis
Aortic Stenosis Resident Survival Guide Microchapters |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Don'ts |
Overview
Aortic stenosis is the progressive narrowing of the diameter of the aortic valve (normal valve area is 3 - 4 cm²) and symptoms are caused by a decrease in stroke volume that leads to decrease perfusion to peripheral tissues, however, symptoms normally appear when the stenosis is ≤ 1.0 cm². The most common etiology of aortic stenosis is calcific aortic valve disease. The management will depend if the patient is symptomatic or asymptomatic. Surgical intervention is the treatment of choice for patients with symptomatic aortic stenosis.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Diagnosis
First Initial Rapid Evaluation of Suspected Aortic Stenosis
Shown below is an algorithm for the First Initial Rapid Evaluation (FIRE) of suspected aortic stenosis.
Determine if the patient has any unstable signs or symptoms ❑ Tachycardia | |||||||||||||||||||||||||||||||||||||||||||||||
Unstable patient | Stable patient | ||||||||||||||||||||||||||||||||||||||||||||||
Identify cardinal signs and symptoms that increase the pretest probability of acute aortic stenosis | |||||||||||||||||||||||||||||||||||||||||||||||
❑ Systolic ejection murmur ❑ Pulsus parvus et tardus ❑ Severe dyspnea ❑ Hypotension | |||||||||||||||||||||||||||||||||||||||||||||||
❑ Treat the underling cause of the decompensation ❑ Do not give nitrates (could cause severe hypotension) | |||||||||||||||||||||||||||||||||||||||||||||||
Patients with severe aortic stenosis that not improve with medical therapy: ❑ Perform urgent AVR | |||||||||||||||||||||||||||||||||||||||||||||||
Complete Diagnostic Approach to Aortic Stenosis
Shown below is an algorithm summarizing the diagnostic approach to aortic stenosis based on the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease [1]
Abbreviations: LVH: Left ventricle hypertrophy; CXR: Chest x-ray; ECG: Electrocardiogram; LBBB: Left bundle branch block; AF: Atrial fibrillation; AVR: Aortic valve replacement; VHD: Valve heart disease; TAVR: Transcatheter aortic valve replacement; TTE: Transthoracic echocardiography
Characterize the symptoms: ❑ Most patients are asymptomatic ❑ Dyspnea on exertion ❑ Exertional dizziness ❑ Exertional angina ❑ Syncope ❑ Chest pain ❑ Palpitations | |||||||||||||||||||||||||||||||||||||||||||||||||
Inquire about past medical history: ❑ Previously healthy ❑ Cardiac disease: ❑ Rheumatic fever ❑ Pulmonary disease | |||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient: Vitals
❑ Respiratory rate: Cardiovascular
❑ Pulses
{{#ev:youtube|MJg257pyt4I|200}}
Respiratory Extremities | |||||||||||||||||||||||||||||||||||||||||||||||||
Order imaging and adjuvant studies: ❑ TTE (Class I; Level of Evidence: B)
❑ ECG (shows non-specific findings):
❑ CXR:
| |||||||||||||||||||||||||||||||||||||||||||||||||
Interpret results from TTE | |||||||||||||||||||||||||||||||||||||||||||||||||
No stenosis (Stage A) ❑ Valve area 2.5-3.5 cm² ❑ No pressure gradient | Mild to moderate stenosis (Stage B) Mild: ❑ Valve area 1.5-2.5 cm² ❑ Pressure gradient ≤ 25 mmHg Moderate: ❑ Valve area 1.0-1.5 cm² ❑ Pressure gradient 25-40 mmHg | Severe stenosis ❑ Valve area ≤ 1.0 cm² ❑ Pressure gradient ≥ 40 mmHg | |||||||||||||||||||||||||||||||||||||||||||||||
❑ Control hypertension (Class I; Level of Evidence: B) ❑ Perform a periodic echocardiogram (Class I; Level of Evidence:B)
| Asymptomatic (Stage C) | Symptomatic (Stage D) | |||||||||||||||||||||||||||||||||||||||||||||||
If patient is unstable: ❑ Administer vasodilation therapy with invasive hemodynamic monitoring (Class IIb; Level of Evidence: C) | |||||||||||||||||||||||||||||||||||||||||||||||||
❑ Control hypertension (Class I; Level of Evidence: B) | Normal LVEF (Stage C1) | LVEF < 50% (Stage C2) | High gradient (ΔP ≥ 40 mmHg) (Stage D1) | ||||||||||||||||||||||||||||||||||||||||||||||
Perform a periodic echocardiogram every 6 - 12 months (Class I; Level of Evidence: B) | Schedule for AVR (Class I; Level of Evidence: A) | Schedule for AVR (Class IIa; Level of Evidence: B-C) | |||||||||||||||||||||||||||||||||||||||||||||||
If aortic velocity ≥ 5 m/s or decrease in exercise tolerance: ❑ Schedule for AVR (Class IIa; Level of Evidence: B) | |||||||||||||||||||||||||||||||||||||||||||||||||
Choice of Intervention
Shown below is an algorithm summarizing the choice of the intervention to aortic stenosis based on the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease [1]
Patient scheduled for AVR | |||||||||||||||||||||||||||||||||
High risk | Low to moderate risk | ||||||||||||||||||||||||||||||||
❑ A multidisciplinary group of physicians with expertise in VHD, cardiac imaging, interventional cardiology, cardiac anesthesia, and cardiac surgery should decide intervention (Surgical AVR or TAVR) (Class I; Level of Evidence: C) ❑ Schedule for TAVR (Class IIa; Level of Evidence: B)[1] [2] | ❑ Schedule for surgical AVR (Class I; Level of Evidence: A) | ||||||||||||||||||||||||||||||||
Evaluation of Surgical and Interventional Cardiac Risk
Shown below is a table to assess the surgical and interventional risk which combines the STS risk estimate, frailty, major organ system dysfunction and procedure-specific impediments.[1]
Low risk | Intermediate risk | High risk | Prohibitive risk | |
---|---|---|---|---|
STS PROM | <4% AND |
4% to 8% OR |
>8% OR |
Predicted risk of death or major morbidity (all-cause) >50% at 1 year OR |
Frailty* | None AND |
1 index OR |
≥2 indices (moderate to severe) OR |
Predicted risk of death or major morbidity (all-cause) >50% at 1 year OR |
Major organ system compromise not to be improved postoperatively | None AND |
1 organ system OR |
No more than 2 organ systems OR |
≥3 organ systems OR |
Procedure-specific impediment** | None |
Possible procedure-specific impediment | Possible procedure-specific impediment | Severe procedure-specific impediment |
STS PROM: Society of Thoracic Surgeons Predicted Risk of Mortality Score.[3]
*Seven frailty indices: Katz Activites of Daily Living (self-sufficient in feeding, bathing, dressing, transferring, toileting and urinary continence) and self-sufficient in deambulation (no walking aid or assist required or 5-meter walk in <6 s).
**Procedure-specific impediment examples: tracheostomy present, heavily calcified ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall or radiation damage.
Type of Valve and Discharge Anticoagulation Therapy
❑ Determine the age of the patient ❑ Check for contraindications for anticoagulation | |||||||||||||||||||||||||||||||||
❑ Patients ≤ 70 years old (Class IIa; Level of Evidence: B), and ❑ No contraindication for anticoagulation | ❑ Patients ≥ 70 years old (Class IIa; Level of Evidence: B), or ❑ Patients with anticoagulant therapy contraindications (Class I; Level of Evidence: C) | ||||||||||||||||||||||||||||||||
Mechanical Prosthesis | Bioprosthesis | ||||||||||||||||||||||||||||||||
Patient with risk factors | Patient without risk factors | ||||||||||||||||||||||||||||||||
❑ Either a bioprosthetic or mechanical valve is reasonable in patients between 60 and 70 years of age. (Class IIa; Level of Evidence: B).
Do's
❑ Give ACE inhibitors to control hypertension in patients with asymptomatic aortic stenosis. [4]
❑ Exercise testing in asymptomatic patients with AS may be considered to elicit exercise-induced symptoms and abnormal blood pressure responses (Class IIb; Level of Evidence: B).
❑ Dobutamine stress echocardiography is reasonable to evaluate patients with low-flow/low-gradient AS and LV dysfunction (Stage D3) (Class IIa; Level of Evidence: B)
❑ Aortic balloon valvotomy might be reasonable as a bridge to surgery in hemodynamically unstable adult patients with AS who are at high risk for AVR or cannot be performed because of serious comorbid conditions.(Class IIb; Level of Evidence: C).
Don'ts
❑ Do not perform a stress test in a symptomatic patient with stage D aortic stenosis (Class III; Level of Evidence: B).
❑ Do not give statins to prevent hemodynamic progression in patients with mild to moderate calcific aortic valve disease (Class III; Level of Evidence: A).
❑ TAVR is not recommended in patients in whom existing comorbidities would preclude the expected benefit from correction of AS (Class III; Level of Evidence: B)
❑ Do not give vasodilators to patients with severe AS as they may cause severe hypotension.
❑ Endocarditis prophylaxis is not indicated in patients with AS. [5]
References
- ↑ 1.0 1.1 1.2 1.3 Nishimura, R. A.; Otto, C. M.; Bonow, R. O.; Carabello, B. A.; Erwin, J. P.; Guyton, R. A.; O'Gara, P. T.; Ruiz, C. E.; Skubas, N. J.; Sorajja, P.; Sundt, T. M.; Thomas, J. D. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000031. ISSN 0009-7322.
- ↑ Smith, Craig R.; Leon, Martin B.; Mack, Michael J.; Miller, D. Craig; Moses, Jeffrey W.; Svensson, Lars G.; Tuzcu, E. Murat; Webb, John G.; Fontana, Gregory P.; Makkar, Raj R.; Williams, Mathew; Dewey, Todd; Kapadia, Samir; Babaliaros, Vasilis; Thourani, Vinod H.; Corso, Paul; Pichard, Augusto D.; Bavaria, Joseph E.; Herrmann, Howard C.; Akin, Jodi J.; Anderson, William N.; Wang, Duolao; Pocock, Stuart J. (2011). "Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients". New England Journal of Medicine. 364 (23): 2187–2198. doi:10.1056/NEJMoa1103510. ISSN 0028-4793.
- ↑ "Online STS Risk Calculator". Retrieved 7 March 2014.
- ↑ Chambers, J. (2005). "The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors". Heart. 92 (3): 420–423. doi:10.1136/hrt.2005.074112. ISSN 1355-6037.
- ↑ Bonow, RO.; Carabello, BA.; Chatterjee, K.; de Leon, AC.; Faxon, DP.; Freed, MD.; Gaasch, WH.; Lytle, BW.; Nishimura, RA. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Unknown parameter
|month=
ignored (help)